Loading...
NPI 1366441743 · Las Vegas, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Raja Mehdi is a hematology & oncology physician provider located in Las Vegas, Nevada. This profile covers 46 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Raja Mehdi |
| Address | 6827 W Tropicana Ave |
| City | Las Vegas |
| State | NV |
| ZIP | 89103 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | July 19, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.3M |
| Medicaid | $85.7K |
Provider-level revenue is strongly Medicare-weighted: the record shows Total Medicare revenue of $1.3M versus Total Medicaid revenue of $85.7K, indicating Medicare is the primary payer by scale for this NPI. This makes the provider effectively a Medicare-centric oncology practice in financial terms rather than a balanced dual-payer operation.
Medicare revenue is highly concentrated in a single high-cost drug: the top three Medicare codes account for 79.7% of Medicare revenue, and J9271 (pembrolizumab) alone represents $868.6K or 69.8% of the provider's Medicare revenue. That concentration implies that access and administration of this immunotherapy product are the dominant drivers of the provider’s Medicare cash flow.
The clinical mix supports an infusion-focused oncology model with office-based visits: Medicare top codes include J9271 (immunotherapy), 96413 (chemotherapy administration), and 99214 (established outpatient E/M), which together dominate revenue. High counts for administration and E/M codes (e.g., J9271: 20.2K claims; 96413: 489 claims; 99214: 789 claims) point to a practice combining frequent drug infusions with regular clinic follow-up visits.
Competitive standing is mixed across code types at the national level: for the revenue-driving immunotherapy code J9271 the provider ranks #383 of 1841 (79th percentile; typical, unremarkable volume for this code), indicating solid but not dominant national activity. By contrast, the provider reports notably above-typical national volume on the E/M code 99214 (rank #20231 of 479517, 96th percentile; notably above typical national volume) and strong participation in the Enhanced Oncology Model payment M0010 (rank #10 of 544, 98th percentile; notably above typical national volume), suggesting above-average engagement in office visits and value-based oncology reporting.
Medicaid billing is also concentrated but at a much smaller scale: the top three Medicaid codes account for 89.6% of Medicaid revenue, with 99214 accounting for $48.8K (56.9%) and 96413 accounting for $24.5K (28.6%). This indicates that, for Medicaid patients, the provider’s revenue is driven primarily by office visits and chemotherapy administration rather than high-cost biologic drug reimbursement.
State-level competitive position on Medicaid is modest: 99214 in-state ranks #886 of 2254 (61st percentile; typical, unremarkable volume in-state), while 96413 ranks #10 of 19 (50th percentile; typical, unremarkable volume in-state). These placements imply the provider is a routine regional participant in oncology visit and chemo administration volume rather than a statewide leader for these services.
Billing patterns show a mix of high-dollar biologic revenue and very high-volume low-dollar supportive drug claims: besides the large J9271 revenue ($868.6K), the provider reports very high claim counts for low-dollar drug codes such as J0185 (22.2K claims, $22.2K revenue) and J1442 (12.5K claims, $12.5K revenue). Operationally, that pattern is consistent with an infusion center that bills both high-cost checkpoint inhibitors and frequent supportive medications (antiemetics, growth factors) which generate many claims but relatively small per-claim payments.
NPI tenure indicates an established practice: the NPI was enumerated 2005-07-19 (~21 years ago), which suggests sustained presence in the market and potential continuity of referral and payer relationships over a long period. Combined with the concentrated Medicare drug revenue, this tenure supports the view of a stable, infusion-centric hematology/oncology operation rather than a new entrant.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
46 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 20,200 | $40 | $868.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 790 | $90 | $73.4K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 490 | $100 | $49.4K |
| J0897 | Injection, denosumab, 1 mg | 2,640 | $20 | $44.9K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 350 | $90 | $31K |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 330 | $80 | $25.1K |
| J0185 | Injection, aprepitant, 1 mg | 22,230 | $1 | $22.2K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 150 | $140 | $20.4K |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community… | 100 | $140 | $13.9K |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 12,540 | $1 | $12.5K |
Showing 1–10 of 46
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
46 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 8 | 40 | 13,000 | $40 | $625.8K |
| J0897 | 44 | 70 | 3,630 | $20 | $94.6K |
| Q5122 | 5 | 10 | 350 | $90 | $37.7K |
| 96413 | 6 | 70 | 210 | $100 | $23.7K |
| 99214 | 184 | 3,610 | 110 | $80 | $19K |
| J3490 | 26 | 50 | 60 | $90 | $12.7K |
| 99215 | 144 | 790 | 40 | $120 | $12.2K |
| M0010 | 1 | 10 | 100 | $70 | $12K |
| Q0138 | 26 | 30 | 24,480 | $1 | $11.2K |
| J0185 | 1 | 10 | 6,240 | $1 | $10.4K |
Showing 1–10 of 46
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 510 | $100 | $48.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 240 | $100 | $24.5K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 60 | $60 | $3.5K |
| 96417 | In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy… | 60 | $50 | $2.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 40 | $60 | $2.2K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 10 | $120 | $1.4K |
| 96368 | The provider administers an intravenous infusion or infusions of multiple medications or substances concurrently with another infusion to prevent, treat, or diagnose a condition or disease. | 100 | $10 | $1.1K |
| 96415 | In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the… | 20 | $50 | $970 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 210 | $1 | $410 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 190 | $1 | $190 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 10 | 20 | 240 | $90 | $189.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 886 | 2,250 | 290 | $60 | $138K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,108 | 2,480 | 330 | $50 | $107.6K |
| 96417 | In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy… | 4 | 10 | 1,150 | $30 | $34.7K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 349 | 360 | 90 | $70 | $28.2K |
| 96415 | In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the… | 7 | 10 | 100 | $20 | $12.8K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 20 | 30 | 150 | $10 | $10.9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 50 | 60 | 2,550 | $1 | $3.3K |
| 96368 | The provider administers an intravenous infusion or infusions of multiple medications or substances concurrently with another infusion to prevent, treat, or diagnose a condition or disease. | 12 | 20 | 180 | $1 | $2.7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 73 | 150 | 180 | $1 | $1.4K |
Other providers in the same ZIP code as Raja Mehdi, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.